(To be Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
National Pharmaceutical Pricing Authority

New Delhi, the 28th July, 2017

ORDER

S.O.2400(E)- In exercise of the powers, conferred by paragraph 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. Number and date specified in column no. 5(a) & 5(b) mentioned in the table below, the National Pharmaceutical Pricing Authority, hereby fixes/revises the prices after excluding excise duty levied prior to GST regime, being subsumed in the GST consequent to its implementation by applying the factor of 0.95905 on existing ceiling price, wherever applicable as specified in column (6) of the table herein below as ceiling prices exclusive of goods and services tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

Table

Sl No	Medicines	Dosage form and Strength	Unit	Existing S.O. No. & Existing Date		Ceiling price
(1)	(2)	(3)	(4)	5(a)	5(b)	(6)
1.	Atropine	Injection 0.6 mg/ml	1 ml	2058(E)	30.06.2017	3.80
2.	Atropine	Ointment 1%	1 gm	2058(E)	30.06.2017	3.43
3.	Atropine	Drops 1%	1 ml	2058(E)	30.06.2017	3.11
4.	Coagulation factor VIII	Powder for Injection 250 IU	Each pack	2058(E)	30.06.2017	3,389.14
5.	Coagulation factor VIII	Powder for Injection 500 IU	Each Pack	2058(E)	30.06.2017	8,316.70
6.	Ethambutol	Tablet 800 mg	1 Tablet	2058(E)	30.06.2017	3.84
7.	Ethambutol	Tablet 600 mg	1 Tablet	2058(E)	30.06.2017	3.21
8.	Ethambutol	Tablet 400 mg	1 Tablet	2058(E)	30.06.2017	2.18
9.	Ethambutol	Tablet 200 mg	1 Tablet	2058(E)	30.06.2017	0.96
10.	Homatropine	Drops 2%	1 ml	2058(E)	30.06.2017	5.64
11.	Human Normal Immunoglobulin		1 ml	2058(E)	30.06.2017	139.98
12.	Abacavir (A) + Lamivudine (B)	Tablet 600 mg (A)+ 300 mg (B)	1 Tablet	2059(E)	30.06.2017	82.69
13.	Abacavir (A) + Lamivudine (B)	Tablet 60 mg (A) + 30 mg (B)	1 Tablet	2059(E)	30.06.2017	18.22
14.	Atazanavir (A) + Ritonavir (B)	Tablet 300 mg (A) + 100 mg (B)	1 Tablet	2059(E)	30.06.2017	89.58

15.	Capecitabine	Tablet 500 mg	1 Tablet	2059(E)	30.06.2017	114.68
16.	Lamivudine (A) + Nevirapine (B) + Stavudine (C)	Tablet 150 mg (A) + 200 mg (B) + 30 mg(C)	1 Tablet	2059(E)	30.06.2017	14.16
17.	Lamivudine (A) + Zidovudine (B)	Tablet 150 mg (A) + 300 mg (B)	1 Tablet	2059(E)	30.06.2017	18.20
18.	Lamivudine (A)+ Nevirapine (B) + Stavudine (C)	Dispersible Tablet 30 mg (A) + 50 mg (B) + 6 mg (C)	1 Tablet	2059(E)	30.06.2017	4.49
19.	Lopinavir (A) + Ritonavir (B)	Tablet 200 mg (A) + 50 mg (B)	1 Tablet	2059(E)	30.06.2017	41.35
20.	Lopinavir (A) + Ritonavir (B)	Tablet 100 mg (A) + 25 mg (B)	1 Tablet	2059(E)	30.06.2017	21.34
21.	Methylprednisolone	Tablet 16 mg	1 Tablet	2059(E)	30.06.2017	8.09
22.	Methylprednisolone	Tablet 8 mg	1 Tablet	2059(E)	30.06.2017	4.63
23.	Methylprednisolone	Injection 40 mg/ml	1 ml	2059(E)	30.06.2017	43.55
24.	Nevirapine	Tablet 200 mg	1 Tablet	2059(E)	30.06.2017	12.99
25.	Nevirapine	Oral Liquid 50 mg/5ml	1 ml	2059(E)	30.06.2017	0.76
26.	Rituximab	Injection 10 mg/ml	1 ml	2059(E)	30.06.2017	688.24
27.	Stavudine (A) + Lamivudine (B)	Tablet 30 mg (A) +150 mg (B)	1 Tablet	2059(E)	30.06.2017	8.66
28.	Zidovudine (A) + Lamivudine (B) + Nevirapine (C)	Tablet 300 mg (A) + 150 mg (B) + 200 mg(C)	1 Tablet	2059(E)	30.06.2017	18.28

Notes:-

(a) All manufacturers of scheduled formulations, selling branded or generic or both the versions of scheduled formulations at price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (6) in the above table plus goods and services tax as applicable, if any.

(b) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (6) in the above table (plus goods and services tax as applicable, if any), shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013 except increase in MRP due to difference of duties and taxes on implementation of goods and services tax.

(c) The manufacturers may add goods and services tax only if they have actually paid or payable to the Government on the ceiling price mentioned in column (6) of the above said table.

(d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (6) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

(e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

(f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

(h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.

(i) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/179/47/2017/F F. No. 8(47)/2017/D.P./NPPA-Div.-II

(Baljit Singh)
Assistant Director